```html

Bagel‑type Interstitial Lung Disease (Bronchiolitis Obliterans)

Overview

Bronchiolitis obliterans (BO), often called bagel‑type interstitial lung disease because the affected airways become ring‑shaped and narrowed like the hole in a bagel, is a rare, progressive obstructive lung disorder. It is characterized by inflammation and fibrosis (scarring) of the small airways (bronchioles), leading to irreversible narrowing or complete blockage.

Although BO can occur at any age, it most commonly appears in adults aged 30–60 years after an inciting injury. In children, a related condition called “constrictive bronchiolitis” may develop after severe infections or exposure to toxic fumes. The exact prevalence is difficult to determine because the disease is under‑diagnosed, but epidemiologic surveys from the United States and Europe estimate an incidence of 0.2–0.5 cases per 100,000 persons per year [1][2].

BO is not a single disease; it is a pattern of lung injury that can result from a variety of causes—including respiratory infections, inhalation of toxic chemicals, certain medications, and graft‑versus‑host disease after bone‑marrow transplantation.

Symptoms

Symptoms develop insidiously and may be mistaken for asthma or chronic obstructive pulmonary disease (COPD). A complete list includes:

• Dyspnea (shortness of breath): Typically progressive, worsening with exertion and, in advanced disease, at rest.
• Dry, non‑productive cough: Persistent, often worse at night.
• Wheezing or whistling breath sounds: Due to airway narrowing.
• Chest tightness or discomfort: May mimic asthma.
• Fatigue: Reduced oxygen delivery leads to easy tiredness.
• Weight loss: Chronic disease and increased work of breathing can reduce appetite.
• Clubbing of fingernails: Seen in 10‑20 % of patients with long‑standing disease.
• Reduced exercise tolerance: Simple activities such as climbing stairs become difficult.
• Recurrent respiratory infections: Stagnant secretions predispose to bacterial overgrowth.

Symptoms often appear weeks to months after the initial trigger, and the rate of progression varies widely—from a few months to several years.

Causes and Risk Factors

Bronchiolitis obliterans is a final common pathway of airway injury. The most common precipitants include:

Inhalational Exposures

• Occupational toxins: Diacetyl (buttery flavoring in microwave popcorn, coffee, e‑cigarettes), chlorine gas, sulfur dioxide, ammonia, and silica.
• Environmental pollutants: Smoke from fires, severe air pollution episodes, and wildfire inhalation.

Infections

• Severe viral infections (e.g., adenovirus, influenza, SARS‑CoV‑2).
• Bacterial pneumonia, especially with Mycoplasma pneumoniae or Staphylococcus aureus.
• Mycobacterial or fungal infections in immunocompromised patients.

Medications and Radiation

• Bleomycin, cyclophosphamide, and certain antibiotics (e.g., nitrofurantoin).
• Radiation therapy to the chest.

Transplant‑Related

• Allogeneic hematopoietic stem‑cell transplantation: Graft‑versus‑host disease (GVHD) of the lung is a leading cause.
• Lung transplantation: Chronic rejection can present as BO.

Autoimmune Disorders

• Rheumatoid arthritis, systemic lupus erythematosus, and sarcoidosis have been linked to BO.

Risk Factors

• Age < 65 years (younger immune systems may mount a vigorous inflammatory reaction).
• Male sex – several registries show a slight male predominance (≈ 55 %).
• Occupational exposure to flavoring chemicals (e.g., workers in microwave‑popcorn factories have a 10‑fold higher risk).
• History of severe respiratory infection or lung injury.
• Underlying immune dysfunction (post‑transplant, HIV, or immunosuppressive therapy).

Diagnosis

Diagnosing BO requires a combination of clinical suspicion, imaging, pulmonary function testing, and, when necessary, lung tissue sampling.

1. Detailed History & Physical Examination

Clinicians look for a temporal link between exposure/infection and symptom onset, and listen for characteristic wheezes or crackles.

2. Pulmonary Function Tests (PFTs)

• Obstructive pattern: Decreased FEV₁/FVC ratio (< 70 %).
• Reduced forced expiratory flow at 25‑75 % of vital capacity (FEF₂₅‑₇₅), reflecting small‑airway disease.
• Often a mixed obstructive‑restrictive picture in advanced disease.

3. High‑Resolution Computed Tomography (HRCT)

HRCT is the imaging gold standard. Typical findings include:

• Bronchial wall thickening and “air‑trapping” on expiratory scans.
• “Mosaic attenuation” pattern.
• Small‑diameter airways with concentric fibrosis producing the “bagel‑type” appearance.

4. Bronchoscopy with Bronchoalveolar Lavage (BAL)

Helps rule out infection and may reveal inflammatory cells (predominantly neutrophils or lymphocytes) suggestive of BO.

5. Lung Biopsy (Surgical or Cryobiopsy)

Reserved for unclear cases. Histology shows:

• Obliterative bronchiolitis with fibro‑inflammatory plugs filling the lumen.
• Fibrotic narrowing of the airway wall.

Because the procedure carries risk, it is performed only when the diagnosis will change management.

6. Laboratory Tests

Used mainly to identify underlying causes (e.g., autoimmune panels, viral PCR, serum IgE). There is no single blood marker for BO.

Treatment Options

There is no cure; treatment aims to halt progression, relieve symptoms, and improve quality of life.

1. Remove or Limit the Trigger

• Immediate cessation of exposure to offending chemicals (e.g., stop working with diacetyl).
• Treatment of active infection with appropriate antibiotics or antivirals.

2. Anti‑Inflammatory Medications

• Corticosteroids: High‑dose oral prednisone (0.5–1 mg/kg/day) for 4‑6 weeks, then taper. Benefits are modest and relapse is common.
• Macrolide antibiotics (azithromycin, clarithromycin): Possess anti‑inflammatory properties; often used long‑term (3–5 mg/kg three times weekly) especially in post‑transplant BO.
• Immunomodulators: Mycophenolate mofetil, azathioprine, or calcineurin inhibitors are considered in GVHD‑related BO.

3. Bronchodilators

Long‑acting β₂‑agonists (LABA) and anticholinergics (tiotropium) improve airflow and reduce dyspnea, similar to COPD management.

4. Pulmonary Rehabilitation

Structured exercise programs improve endurance, reduce breathlessness, and enhance overall health.

5. Supplemental Oxygen

Prescribed when resting SpO₂ < 90 % or during exertion. Long‑term oxygen therapy has been shown to improve survival in chronic lung diseases.

6. Advanced Therapies

• Lung transplantation: Considered for end‑stage disease when FEV₁ < 30 % predicted and quality of life is severely limited. Five‑year survival after transplantation is approximately 55 % [3].
• Experimental therapies: Small trials of anti‑fibrotic agents (pirfenidone, nintedanib) are ongoing, but evidence is not yet conclusive.

Living with Bagel‑type Interstitial Lung Disease (Bronchiolitis Obliterans)

Effective self‑management can slow disease progression and maintain independence.

Daily Management Tips

• Medication adherence: Use a weekly pill organizer and set reminders.
• Inhaler technique: Demonstrate proper use at each clinic visit; consider a spacer with steroids.
• Vaccinations: Annual flu shot, COVID‑19 booster, and pneumococcal vaccines (PCV20 or PCV15 + PPSV23) reduce infection risk.
• Air quality: Use HEPA filters at home, avoid smoking, and stay indoors on high‑pollution days.
• Physical activity: Aim for 150 minutes of moderate aerobic activity per week; incorporate breathing exercises (pursed‑lip breathing, diaphragmatic breathing).
• Nutrition: High‑protein, calorie‑dense diet to counteract weight loss; consider a dietitian if appetite is poor.
• Monitor symptoms: Keep a daily log of shortness of breath scores, peak flow readings (if prescribed), and any new cough or fever.
• Regular follow‑up: Pulmonology visits every 3–6 months, or sooner if symptoms change.

Prevention

Because BO often follows an identifiable insult, primary prevention focuses on exposure control and early treatment of infections.

• Workplace safety: Use proper ventilation, personal protective equipment (PPE), and regular environmental monitoring for chemicals like diacetyl.
• Smoking cessation: Smoking synergistically worsens airway injury.
• Prompt treatment of respiratory infections: Seek care early for persistent cough or fever.
• Vaccination: Influenza, COVID‑19, and pneumococcal vaccines are recommended for all adults, especially those with lung disease.
• Infection control after transplant: Strict adherence to prophylactic antimicrobial regimens and regular GVHD surveillance.

Complications

If left untreated or if the disease progresses despite therapy, complications may include:

• Respiratory failure: Requires supplemental oxygen or mechanical ventilation.
• Cor pulmonale: Right‑heart strain secondary to chronic hypoxia.
• Recurrent bacterial pneumonia: Due to impaired mucociliary clearance.
• Pulmonary hypertension: Develops in up to 15 % of advanced cases.
• Reduced functional status: Loss of independence, increased fall risk.
• Psychological impact: Anxiety, depression, and social isolation are common; referral to mental‑health services is advised.

When to Seek Emergency Care

References

1. Mayo Clinic. “Bronchiolitis Obliterans.” Updated 2023. https://www.mayoclinic.org
2. Centers for Disease Control and Prevention. “Occupational Exposure to Diacetyl and Bronchiolitis Obliterans.” 2022. https://www.cdc.gov
3. International Society for Heart and Lung Transplantation. “Registry Report – Lung Transplantation 2024.” https://ishlt.org
4. National Institutes of Health. “Bronchiolitis Obliterans after Stem Cell Transplant.” 2021. https://www.ncbi.nlm.nih.gov
5. Cleveland Clinic. “Pulmonary Rehabilitation.” 2023. https://my.clevelandclinic.org

```